Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VOR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVor Biopharma raises $75M in private placement at $14.05/share, diluting shareholders 10%
Filed March 27, 2026 · Period ending March 26, 2026 · ~1 min read
Key Changes
-
high
Company sold 5.3M shares at $14.05 to TCGX-affiliated investors for $75M gross proceeds, closing March 30. Funds will advance clinical pipeline and general operations.
Item 1.01 verify on EDGAR → -
high
Private placement creates ~10% dilution, increasing outstanding shares from 48.8M to 54.2M. Existing shareholders' ownership percentage reduced proportionally.
Item 1.01 verify on EDGAR → -
medium
Company must file resale registration within 30 days and get it effective within 60 days or face liquidated damages. Once registered, new shares become freely tradable.
Item 1.01 verify on EDGAR → -
medium
Shares sold to qualified institutional buyers and accredited investors under Section 4(a)(2) exemption without public offering or general solicitation.
Item 3.02 verify on EDGAR →
Summary
Vor Biopharma secured $75 million through a private placement with TCGX-affiliated institutional investors, selling 5.3 million shares at $14.05 each. The transaction closes March 30 and will fund clinical development of the company's drug pipeline. While the capital provides runway for advancing trials, existing shareholders face approximately 10% dilution as outstanding shares increase to 54.2 million.
The deal includes registration rights requiring Vor to register the new shares for resale within strict deadlines—30 days to file, 60 days to effectiveness—or pay liquidated damages. Once registered, these shares can be freely sold, potentially creating selling pressure.
The $14.05 price point and investor quality (qualified institutional buyers) suggest institutional confidence, but retail holders should monitor whether the company meets registration deadlines and how quickly new shares hit the market. Watch for the S-3 registration filing in late April and any updates on clinical trial progress that justify the dilution. The use of proceeds remains general, so upcoming pipeline announcements will indicate whether this capital accelerates meaningful value creation.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Placement”).
The company secured $75 million in gross proceeds by selling approximately 5.3 million shares at $14.05 per share to investors affiliated with TCGX. The transaction is expected to close on March 30, 2026, and will increase total outstanding shares to approximately 54.2 million. Proceeds will fund clinical pipeline development and general corporate purposes.
Added in current filing · verify on EDGAR →
Upon the closing of the Private Placement, the Company will have 54,185,582 shares of common stock outstanding.
The private placement will result in approximately 5.3 million new shares being issued, representing roughly 10% dilution to existing shareholders based on the post-closing share count of 54.2 million shares. This is material dilution that will reduce existing shareholders' ownership percentage.
Added in current filing · verify on EDGAR →
Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-3 (the “Registration Statement”) to register for resale the Shares within 30 days of the closing date of the Private Placement and to use its reasonable best efforts to have the Registration Statement declared effective as soon as possible, but no later than 60 days after the closing date of the Private Placement, subject to extension under the terms of the Registration Rights Agreement. The Registration Rights Agreement provides for liquidated damages payable to the Investors if the Company fails to meet certain filing or effectiveness deadlines, subject to specified caps.
The company must file a resale registration statement within 30 days of closing and have it declared effective within 60 days, or face liquidated damages to the investors. This creates near-term regulatory obligations and potential financial penalties if deadlines are missed, plus the newly issued shares will become freely tradable once registered, potentially creating selling pressure.
Added in current filing · verify on EDGAR →
The Company intends to use the net proceeds from the Private Placement to advance development of its clinical pipeline and for general corporate purposes.
The $75 million in gross proceeds (net proceeds will be lower after transaction costs) will be used to fund clinical development programs and general operations. This provides the company with additional runway to advance its drug candidates through clinical trials.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Item 3.02 — Unregistered Sales of Equity Securities filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a) (2) of the Securities Act. Each Investor has represented that it is a “qualified institutional buyer,” as defined in Rule 144A under the Securities Act or an institutional “accredited investor” (as defined in Rule 501(a) under the Securities Act), that it is purchasing the Shares solely for such Investor’s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the Shares in violation of the Securities Act. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising.
Vor Biopharma sold unregistered shares in a private placement to qualified institutional buyers and accredited investors under Section 4(a)(2) exemption. The shares were sold without public offering or general solicitation, and investors represented they are purchasing for their own accounts without intent to resell in violation of securities laws. This is a capital-raising transaction that dilutes existing shareholders but provides the company with funding.
Event · Item 7.01 — Regulation FD Disclosure
Vor Biopharma announced a private placement financing via press release under Regulation FD.
Added in current filing · verify on EDGAR →
On March 27, 2026, the Company issued a press release announcing the Private Placement.
Vor Biopharma disclosed a private placement financing transaction through a press release. The 8-K provides no details about the size, terms, or investors involved in the private placement; those details would be in the attached press release (Exhibit 99.1). This is a Regulation FD disclosure, meaning the company is publicly releasing material non-public information to ensure fair access.
Event · Item 9.01 — Financial Statements and Exhibits
Vor Biopharma disclosed a private placement financing with securities purchase and registration rights agreements.
Added in current filing · verify on EDGAR →
the Company’s expectations regarding the closing of the Private Placement and the use of proceeds therefrom, the anticipated filing of a registration statement to cover resales of the Shares
Vor Biopharma announced a private placement of securities. The company expects to close the transaction and use the proceeds for unspecified purposes. A registration statement will be filed to allow resale of the shares issued in the private placement.
Added in current filing · verify on EDGAR →
Form of Securities Purchase Agreement.
The company entered into a securities purchase agreement governing the terms of the private placement. The form agreement is attached as an exhibit but the specific terms (price, number of shares, investor identity) are not disclosed in the 8-K body.
Added in current filing · verify on EDGAR →
Form of Registration Rights Agreement.
Investors in the private placement received registration rights, obligating Vor to register their shares for resale. This is standard for private placements and allows investors to sell shares publicly once registered.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify